PMN penny stock againIt is already too late for that compound , there is plenty of them in developement and Mab doesn't have the regulator's favor because it is too costly and to complicated to manage. The problem with thoses crooks is they never intended to conduct any clinical trials they just wanted the prefect deal to fulfill their pockets, and that deal never came and now it is too late.
https://link.springer.com/article/10.1007/s40291-024-00738-6#Fig2